Core Viewpoint - Ademi LLP is investigating FONAR Corporation for potential breaches of fiduciary duty and other legal violations related to a recent transaction involving the company's management and board members [1] Transaction Details - FONAR stockholders will receive $19.00 per share for common stock, $19.00 per share for Class B common stock, $6.34 per share for Class C common stock, and $10.50 per share for Class A non-voting preferred stock [1] - The transaction agreement imposes significant penalties on FONAR for accepting competing bids, which may limit shareholder options [1] Investigation Focus - The investigation is centered on the conduct of FONAR's board of directors and whether they are fulfilling their fiduciary duties to all shareholders [1] - Ademi LLP specializes in shareholder litigation concerning buyouts, mergers, and individual shareholder rights [1]

Financial Performance - Total Revenues - Net increased by 2% to $25.5 million for the quarter ended December 31, 2025, and by 3% to $51.6 million for the six-month period[5]. - Net Income for the quarter increased by 15% to $2.5 million, while it decreased by 16% to $5.2 million for the six-month period[7]. - Diluted Net Income per Common Share increased by 7% to $0.31 for the quarter, but decreased by 11% to $0.66 for the six-month period[8]. - Income from Operations for the quarter increased by 23% to $3.0 million, while it decreased by 12% to $6.2 million for the six-month period[6]. - Total revenues for the six months ended December 31, 2025, increased to $51,590,000, up from $49,910,000 in 2024, representing a growth of approximately 3.4%[45]. - Consolidated net income for the six months ended December 31, 2025, was $5,209,000, compared to $6,205,000 in 2024, reflecting a decrease of about 16.0%[45]. - Basic net income per common share available to common stockholders decreased to $0.66 for the six months ended December 31, 2025, down from $0.76 in 2024, a decline of 13.2%[45]. Cash and Cash Equivalents - Cash and cash equivalents decreased by 6% to $53.0 million as of December 31, 2025, compared to $56.3 million at the end of the previous fiscal year[4]. - FONAR's cash and cash equivalents as of December 31, 2025, were $52.977 million, a decrease from $56.334 million as of June 30, 2025[37]. - Cash and cash equivalents at the end of the period were $52,977,000, down from $53,583,000 at the end of the same period in 2024, a decrease of about 1.1%[47]. Expenses - Selling, general & administrative expenses decreased by 10% to $6.2 million for the quarter, but increased by 8% to $13.1 million for the six-month period[9]. - Total costs and expenses for the six months ended December 31, 2025, were $45,396,000, an increase from $42,869,000 in 2024, marking a rise of approximately 5.9%[45]. - Research and development expenses for the three months ended December 31, 2025, were $455,000, an increase from $376,000 in the prior year[43]. - Research and development expenses increased to $895,000 for the six months ended December 31, 2025, up from $683,000 in 2024, representing a growth of about 31.1%[45]. - The company incurred a cost of $500,000 for a non-compete contract during the six months ended December 31, 2025[47]. Operational Metrics - The company managed 45 MRI scanners as of December 31, 2025, up from 9 in 2009[3]. - Scan volume in the second quarter was 54,846, a 3.3% increase compared to the same quarter in the previous fiscal year[18]. - FONAR's management and other fees revenue was $12.897 million for the three months ended December 31, 2025, compared to $12.189 million in the same period of 2024, indicating a growth of approximately 5.8%[43]. - Management and other fees rose to $25,838,000 in 2025, compared to $24,518,000 in 2024, an increase of approximately 5.4%[45]. Assets and Liabilities - Total assets increased to $217.224 million as of December 31, 2025, compared to $216.908 million as of June 30, 2025[41]. - The company’s total liabilities decreased to $54.362 million as of December 31, 2025, down from $56.803 million as of June 30, 2025[39]. - The company reported a decrease in accounts payable by $609,000 for the six months ended December 31, 2025, compared to a decrease of $903,000 in 2024[47]. Merger Agreement - A definitive merger agreement was signed on December 29, 2025, increasing the cash offer to $19.00 per common share[4]. Technology Development - The company has ongoing technology development for visualizing and quantifying cerebrospinal fluid dynamics, which is expected to enhance diagnostic capabilities[31]. - FONAR's UPRIGHT® Multi-Position™ MRI remains the only scanner licensed under its substantial list of patents, which includes recent innovations in weight-bearing MRI imaging[33].

Financial Performance - For the six-month period ended December 31, 2025, the company reported net income of $5.2 million on revenues of $51.6 million, compared to net income of $6.2 million on revenues of $50.0 million for the same period in 2024[144]. - Operating income decreased from $7.0 million for the six months ended December 31, 2024, to $6.2 million for the same period in 2025, while costs and expenses increased by 5.9% to $45.4 million[149]. - Consolidated net revenues increased by 3.3% to $51.6 million for the first six months of fiscal 2026, compared to $50.0 million for the same period in fiscal 2025[165]. - Total costs and expenses rose by 5.9% to $45.4 million in the first six months of fiscal 2026, up from $42.9 million in the first six months of fiscal 2025[165]. - Operating income decreased to $6.2 million in the first six months of fiscal 2026, down from $7.0 million in the same period of fiscal 2025[165]. Revenue Sources - Revenues from product sales and service and repair fees increased from $4.0 million for the first six months of fiscal 2025 to $4.9 million for the first six months of fiscal 2026[146]. - HMCA revenues increased by 1.6% to $46.7 million for the first six months of fiscal 2026, while the percentage of total revenues from this segment decreased slightly to 90.5%[154]. - Revenues from MRI product sales increased to $442,000 for the first six months of fiscal 2026 from $145,000 for the same period in fiscal 2025[161]. - Service and repair fees revenue increased to $4.5 million for the six-month period ended December 31, 2025, from $3.8 million for the same period in 2024[162]. Operational Challenges - Medicare reimbursement rates for MRI scans are flat year over year for calendar year 2026, creating operational challenges due to rising costs[160]. Cash Flow and Investments - Cash provided by operating activities was $1.9 million for the first six months of fiscal 2026, primarily due to net income of $5.2 million[173]. - Cash used in investing activities totaled $2.8 million for the first six months of fiscal 2026, including $2.3 million for property and equipment purchases[174]. Liabilities and Working Capital - Total liabilities decreased by 4.3% to $54.4 million at December 31, 2025, from $56.8 million at June 30, 2025[178]. - Working capital increased to $129.4 million at December 31, 2025, up from $127.5 million at June 30, 2025[180]. Future Plans - The company plans to open an additional location on Long Island, New York, with expected costs of approximately $900,000 for a new scanner and related buildout[184]. - The company believes its existing cash balances and internal cash generating capabilities are sufficient to finance capital expenditures and operations for at least the next 12 months[188]. Merger and Acquisition - The company is subject to customary restrictions on soliciting alternative acquisition proposals as part of the proposed going-private transaction[141]. - The proposed merger agreement includes a cash consideration of $19.00 per share for Common Stock and Class B Common Stock, and $6.34 per share for Class C Common Stock[139]. Research and Development - Research and development expenses increased by 31.0% to $895,000 for the first six months of fiscal 2026, compared to $683,000 for the same period in fiscal 2025[169]. Scans Performance - The aggregate number of scans performed by the sites owned and managed by the company increased to 109,952 scans from 106,168 scans in the first half of fiscal 2025[148].

Core Viewpoint FONAR Corporation reported its financial results for the second quarter of fiscal 2026, highlighting growth in revenues and net income for the quarter, while facing a decline in net income for the six-month period. The company continues to expand its diagnostic imaging management subsidiary, Health Management Company of America (HMCA), which is crucial for its revenue generation. Financial Results - Total Revenues-Net for the quarter ended December 31, 2025, increased by 2% to $25.5 million compared to $25.0 million for the same quarter in 2024 [2] - Total Revenues-Net for the six-month period ended December 31, 2025, increased by 3% to $51.6 million compared to $50.0 million for the same period in 2024 [2] Income from Operations - Income from Operations for the quarter ended December 31, 2025, increased by 23% to $3.0 million compared to $2.4 million for the same quarter in 2024 [3] - Income from Operations for the six-month period ended December 31, 2025, decreased by 12% to $6.2 million compared to $7.0 million for the same period in 2024 [3] Net Income - Net Income for the quarter ended December 31, 2025, increased by 15% to $2.5 million compared to $2.2 million for the same quarter in 2024 [4] - Net Income for the six-month period ended December 31, 2025, decreased by 16% to $5.2 million compared to $6.2 million for the same period in 2024 [4] Earnings Per Share - Diluted Net Income per Common Share for the quarter ended December 31, 2025, increased by 7% to $0.31 compared to $0.29 for the same quarter in 2024 [5] - Diluted Net Income per Common Share for the six-month period ended December 31, 2025, decreased by 11% to $0.66 compared to $0.74 for the same period in 2024 [5] Expenses - Selling, general & administrative expenses (SG&A) for the quarter ended December 31, 2025, decreased by 10% to $6.2 million compared to $6.9 million for the same quarter in 2024 [6] - SG&A for the six-month period ended December 31, 2025, increased by 8% to $13.1 million compared to $12.1 million for the same period in 2024 [6] Cash Flow - Operating Cash Flow for the six-month period ended December 31, 2025, decreased by 52% to $1.9 million compared to $3.9 million for the same period in 2024 [7] Balance Sheet - Cash and cash equivalents and short-term investments were $53.1 million at December 31, 2025, compared to $56.3 million at June 30, 2025 [8] - Total Current Assets at December 31, 2025, were $143.7 million compared to $144.7 million at June 30, 2025 [9] - Total Assets were $217.2 million at December 31, 2025, compared to $216.9 million at June 30, 2025 [9] - Total Current Liabilities were $14.4 million at December 31, 2025, compared to $17.1 million at June 30, 2025 [9] - Total Liabilities at December 31, 2025, were $54.4 million compared to $56.8 million at June 30, 2025 [9] - Total Stockholders' Equity at December 31, 2025, was $162.9 million compared to $160.1 million at June 30, 2025 [10] Management Discussion - The Chairman and CEO, Timothy Damadian, noted that HMCA continues to grow, with a scan volume of 54,846 in the second quarter of Fiscal 2026, which is 3.3% higher than the same quarter in Fiscal 2025 [14] - A high-field MRI was added at an existing site, leading to a 30% increase in scan volume since its installation [14] - The company is actively seeking new locations to enhance its service network in New York and Florida [14] Merger Agreement - On December 29, 2025, the company announced a definitive merger agreement for a "Take Private" offer, increasing the cash offer per common share to $19.00 from the previous $17.25 [15]

Group 1 - The core issue is the investigation by Kaskela Law LLC into the proposed buyout of FONAR Corp. to assess whether the buyout price of $19.00 per share significantly undervalues the company's shares and disadvantages its investors [1][2][3] - FONAR announced the acquisition agreement on December 29, 2025, which will result in shareholders being cashed out and the company's shares ceasing to be publicly traded [2] - The investigation aims to determine if FONAR's investors are receiving adequate financial compensation for their shares and whether the company's officers or directors have breached their fiduciary duties or violated securities laws in the sale agreement [3]

Core Viewpoint - Levi & Korsinsky, LLP has initiated an investigation into potential breaches of fiduciary duty by the officers and directors of FONAR Corporation related to a management-led take-private merger approved in December 2025 [2]. Group 1 - The investigation focuses on whether the actions taken by FONAR's management and board were in violation of their fiduciary responsibilities [2]. - FONAR Corporation is publicly traded on NASDAQ under the ticker symbol FONR [1]. - Levi & Korsinsky, LLP is a nationally recognized law firm with expertise in securities litigation and has successfully recovered hundreds of millions of dollars for shareholders [3].

Merger Investigations - RAPT Therapeutics will be acquired by GlaxoSmithKline LLC for $58.00 per share, with an estimated aggregate equity value of $2.2 billion. The investigation focuses on whether the RAPT Board breached its fiduciary duties by failing to conduct a fair process and whether the deal provides fair value to shareholders [2] - Calavo Growers will be acquired by Mission Produce, Inc. for $27.00 per share, consisting of $14.85 in cash and 0.9790 shares of Mission for each share of Calavo, valuing Calavo at approximately $430 million. The investigation concerns potential breaches of fiduciary duties by the Calavo Board regarding the fairness of the deal [4] - Penumbra will be acquired by Boston Scientific Corporation in a cash and stock transaction valuing Penumbra at $374 per share, with an enterprise value of approximately $14.5 billion. The investigation examines whether the Penumbra Board failed to conduct a fair process and whether the deal consideration is fair [6] - FONAR Corporation will be acquired by FONAR, LLC and FONAR Acquisition Sub, Inc. for $19.00 per share in an all-cash transaction. The investigation looks into whether the FONAR Board breached its fiduciary duties by not ensuring a fair process and fair value for shareholders [8]

Group 1 - The last commentary on FONAR Corporation (FONR) was in September of the previous year, resulting in a downgrade of the company due to shares trading at $15.60, which subsequently fell below $14 [1] - The company specializes in magnetic resonance imaging (MRI) technology [1] Group 2 - The commentary reflects a strategy focused on investing in undervalued profitable stocks with strong balance sheets and minimal debt [1] - The approach includes writing calls against positions to generate additional income and managing risk through position sizing and trailing stop losses [1]

Core Viewpoint - Monteverde & Associates PC is investigating FONAR Corporation regarding its proposed sale to affiliates of CEO Timothy Damadian, questioning the fairness of the deal for shareholders [1]. Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1]. - The firm is located in the Empire State Building, New York City, and specializes in class action securities litigation [2]. Transaction Details - Under the proposed transaction, FONAR's Class B common stockholders will receive $19.00 per share, while Class C common stockholders will receive $6.34 per share [1].

FDA Approvals & Rejections - ARS Pharma's neffy, a needle-free epinephrine nasal spray for emergency treatment of Type I allergic reactions, received approval in China, with commercial availability expected in spring 2026. The product generated $31.3 million in U.S. revenue in Q3 2025 [3][4]. - Vanda Pharmaceuticals' NEREUS, an oral NK-1 receptor antagonist for preventing motion-induced vomiting, received FDA approval, marking the first new treatment for motion sickness in over 40 years. The drug demonstrated a meaningful reduction in vomiting in clinical trials [5][6]. Clinical Trials - Breakthroughs & Setbacks - InflaRx's analyses from a halted Phase 3 trial of Vilobelimab in pyoderma gangrenosum indicated potential efficacy signals with longer treatment duration, prompting plans to discuss alternative endpoints with the FDA [15][17]. - SELLAS reported that survival in its Phase 3 REGAL trial for Galinpepimut-S (GPS) in acute myeloid leukaemia is extending longer than anticipated, potentially increasing the likelihood of a positive outcome [18][19]. - Ultragenyx announced that its Phase 3 studies for Setrusumab in Osteogenesis Imperfecta failed to meet primary endpoints, leading to a decline in investor confidence [20][21]. - Genmab decided to discontinue clinical development of Acasunlimab to focus on higher-priority programs, with no impact expected on its full-year 2025 financial guidance [22][23]. Corporate Actions - FONAR Corporation agreed to be taken private by a CEO-led acquisition group for $19.00 per share, valuing the transaction at a significant premium. The deal is expected to close in Q3 2026, subject to shareholder approval [12][13][14].